

Neuromarkers of Fatigue and Cognitive Complaints Following Chemotherapy for Breast Cancer: A Prospective fMRI Investigation

Mary K. Askren¹

Mi Sook Jung^{2,3}

Marc G. Berman⁴

Min Zhang²

Barbara Therrien²

Scott Peltier²

Lynn Ossher²

Daniel F. Hayes²

Patricia A. Reuter-Lorenz²

Bernadine Cimprich²

¹Integrated Brain Imaging Center, Department of Radiology, University of Washington; ²University of Michigan; ³Chungam National University; ⁴Department of Psychology, University of Chicago

Address correspondence to:

Mary K. Askren, Ph.D.
Integrated Brain Imaging Center
University of Washington
Email: askren@uw.edu
Phone: 206-221-9138
Fax: 206-543-3495

Table S1. VWMT Performance and fMRI and Self-reported Attentional Function, Fatigue, and Worry

	Chemotherapy group (n = 28)		Non-chemotherapy group (n = 37)		Control group (n = 32)	
	Pre-treatment	Post-treatment	Pre-treatment	Post-treatment	Pre-treatment	Post-treatment
	M ± SD (Range)	M ± SD (Range)	M ± SD (Range)	M ± SD (Range)	M ± SD (Range)	M ± SD (Range)
Error rate						
Unfamiliar	0.04 ± 0.07 (0.00 – 0.33)	0.04 ± 0.06 (0.00 – 0.22)	0.02 ± 0.04 (0.00 – 0.17)	0.02 ± 0.04 (0.00 – 0.17)	0.02 ± 0.04 (0.00 – 0.21)	0.03 ± 0.04 (0.00 – 0.13)
Familiar	0.09 ± 0.08 (0.00 – 0.29)	0.09 ± 0.07 (0.00 – 0.27)	0.08 ± 0.08 (0.00 – 0.31)	0.07 ± 0.07 (0.00 – 0.27)	0.06 ± 0.05 (0.00 – 0.15)	0.06 ± 0.06 (0.00 – 0.23)
Overall	0.07 ± 0.07 (0.00 – 0.25)	0.08 ± 0.06 (0.00 – 0.24)	0.06 ± 0.06 (0.00 – 0.24)	0.05 ± 0.06 (0.00 – 0.22)	0.04 ± 0.04 (0.00 – 0.17)	0.05 ± 0.04 (0.00 – 0.19)
Reaction time						
Unfamiliar	1073.16 ± 200.83 (767.75 – 1572.63)	1054.89 ± 194.17 (722.26 – 1598.82)	1086.89 ± 164.66 (770.67 – 1517.80)	1050.08 ± 151.58 (799.96 – 1409.00)	1056.40 ± 170.45 ^b (758.88 – 1467.38)	1005.52 ± 194.35 ^b (729.38 – 1507.96)
Familiar	1178.20 ± 180.45 (867.17 – 1648.00)	1172.89 ± 190.46 (868.80 – 1703.69)	1204.44 ± 176.63 (855.52 – 1724.71)	1181.16 ± 158.19 (930.74 – 1626.09)	1177.99 ± 208.42 ^b (749.41 – 1761.94)	1128.68 ± 231.90 ^b (763.19 – 1736.71)
Overall	1143.19 ± 183.32 (834.03 – 1622.88)	1133.56 ± 187.95 (832.08 – 1668.73)	1165.26 ± 169.49 (827.24 – 1655.74)	1137.46 ± 151.81 (896.68 – 1553.73)	1137.46 ± 192.84 ^b (752.56 – 1663.75)	1087.62 ± 217.79 ^b (751.92 – 1660.46)
Executive Network						
Mean	4.22 ± 3.18 (-3.66 – 12.91)	4.72 ± 3.22 (-0.85 – 12.09)	3.64 ± 2.97 (-1.58 – 10.93)	4.91 ± 3.07 (-0.32 – 16.78)	4.04 ± 4.27 (-3.72 – 15.69)	5.09 ± 2.99 (-0.76 – 13.45)
Variance	39.57 ± 20.68 (10.62 – 120.41)	34.52 ± 20.60 (2.83 – 77.82)	30.75 ± 14.34 (9.33 – 71.58)	31.42 ± 14.91 (8.11 – 77.07)	36.76 ± 32.25 (0.61 – 188.81)	33.59 ± 14.18 (3.76 – 72.91)
AFI	7.30 ± 1.61 ^b (3.88 – 9.63)	6.59 ± 1.62 ^b (3.31 – 9.88)	7.35 ± 1.78 (2.50 – 9.88)	7.21 ± 1.92 (3.38 – 9.88)	7.52 ± 1.48 (4.81 – 9.81)	7.07 ± 1.74 (2.63 – 9.75)
Fatigue	13.39 ± 10.87 ^b (0.00 – 37.00)	17.89 ± 8.56 ^{a,b} (2.00 – 37.00)	9.56 ± 7.72 (1.00 – 36.00)	10.43 ± 8.44 ^a (1.00 – 30.00)	8.09 ± 7.82 (0.00 – 30.00)	10.84 ± 11.08 ^a (0.00 – 40.00)
Worry	2.57 ± 0.82 (1.00 – 4.00)	2.73 ± 1.23 (1.00 – 5.00)	2.19 ± 0.84 (1.00 – 4.00)	2.15 ± 0.88 (1.00 – 4.00)	2.29 ± 0.86 (1.00 – 5.00)	2.25 ± 0.83 (1.00 – 4.00)

Abbreviation: AFI = Attentional Function Index.

^ap < .05 for One-Way ANOVA across groups. ^bp < .05 for paired t-test between pre-treatment and post-treatment assessments.

One non-chemotherapy participant was missing fatigue, AFI, and worry self-reports at the pre-assessment timepoint. One chemotherapy participant was missing worry self-report data at the pre-assessment timepoint. One chemotherapy participant was missing fatigue, AFI, and worry self-reports at the post-assessment timepoint.